Myasthenia Gravis, Generalized

Neurology
7
Pipeline Programs
6
Companies
6
Clinical Trials
1 recruiting
2
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
3
0
2
2
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 5 programs with unclassified modality

On Market (2)

Approved therapies currently available

Catalyst Pharmaceuticals
FIRDAPSEApproved
amifampridine phosphate
Catalyst Pharmaceuticals
oral2018
UP
ZILBRYSQApproved
zilucoplan
UCB Pharma
Complement Inhibitor [EPC]subcutaneous2023

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Catalyst Pharmaceuticals
Catalyst PharmaceuticalsCORAL GABLES, FL
1 program
1
1
Amifampridine PhosphatePhase 31 trial
Active Trials
NCT03304054CompletedEst. Mar 2020
UP
UCB PharmaBelgium - Brussels
1 program
1
1
zilucoplanPhase 31 trial
Active Trials
NCT04115293Completed174Est. Dec 2021
DT
1 program
1
DNTH103Phase 21 trial
Active Trials
NCT06282159Active Not RecruitingEst. Aug 2027
Cartesian Therapeutics
1 program
1
Descartes-08Phase 21 trial
Active Trials
NCT04146051Active Not RecruitingEst. Mar 2026
Grifols
GrifolsNEW YORK, NY
1 program
1
IGIV-CPhase 21 trial
Active Trials
NCT02473952CompletedEst. Jan 2018
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
RavulizumabN/AMonoclonal Antibody1 trial
Active Trials
NCT06909253Recruiting50Est. Dec 2029

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
UCB Pharmazilucoplan
Catalyst PharmaceuticalsAmifampridine Phosphate
Dianthus TherapeuticsDNTH103
Cartesian TherapeuticsDescartes-08
GrifolsIGIV-C
AstraZenecaRavulizumab

Clinical Trials (6)

Total enrollment: 224 patients across 6 trials

NCT04115293UCB Pharmazilucoplan

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Start: Sep 2019Est. completion: Dec 2021174 patients
Phase 3Completed
NCT03304054Catalyst PharmaceuticalsAmifampridine Phosphate

Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG

Start: Apr 2018Est. completion: Mar 2020
Phase 3Completed
NCT06282159Dianthus TherapeuticsDNTH103

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Start: Feb 2024Est. completion: Aug 2027
Phase 2Active Not Recruiting
NCT04146051Cartesian TherapeuticsDescartes-08

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Start: Dec 2019Est. completion: Mar 2026
Phase 2Active Not Recruiting
NCT02473952GrifolsIGIV-C

A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis

Start: Aug 2015Est. completion: Jan 2018
Phase 2Completed
NCT06909253AstraZenecaRavulizumab

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Start: May 2025Est. completion: Dec 202950 patients
N/ARecruiting

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
10h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
10h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
10h ago

Director of Finance

CoMind
London, UK
10h ago

Electronics Engineering Manager

CoMind
London, UK
10h ago

Director of Information Technology

Zavation Medical Products
10h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 224 patients
6 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)